Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on November 24, 2021. The report serves to disclose provisional dividend dates for the fiscal year 2022 to U.S. investors.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is exclusively focused on corporate governance regarding dividend distribution schedules.
Material Changes
No material changes to financial performance or operations are reported in this filing. The content is limited to the announcement of future dates for dividend payments.
Guidance, Outlook, and Management Commentary
Management has announced the indicative schedule for the 2022 dividend payments. The filing includes specific dates for the Results Announcement, Ex-dividend date, Record date, Last date for DRIP elections, and Payable date for all four quarters of 2022. Management notes that these dates are indicative and may be subject to change.
- Q1 2022: Payable Thursday, July 7, 2022.
- Q2 2022: Payable Thursday, October 6, 2022.
- Q3 2022: Payable Thursday, January 12, 2023.
- Q4 2022 (Final): Payable Thursday, April 13, 2023.
Investor Verification Checklist
- Verify the final dividend dates against future announcements, as the current dates are indicative.
- Confirm the specific dividend per share amounts, which are not included in this filing.
- Check for any subsequent filings regarding changes to the DRIP election deadlines.